SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Xue, Wei ^a   Metheringham, Rachael L ^a   Brentville, Victoria A ^a   Gunn, Barbara ^a   Symonds, Peter ^a   Yagita, Hideo ^b   Ramage, Judith M ^c   Durrant, Lindy G ^a,c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cancer immunotherapy; CD4+ T cells; CD8+ T cells; NY ESO 1; targeting antigen presenting cells

Indexed keywords

CD64 ANTIGEN; CHECKPOINT KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; EPITOPE; NY ESO 1 ANTIGEN; SCIB2 VACCINE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE CHECKPOINT; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CYTOTOXICITY; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; MELANOMA; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SPLEEN CELL; SURVIVAL RATE; T CELL DEPLETION; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 84974777258     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1169353     Document Type: Article

References (64)

1. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; 10.1056/NEJMoa1003466
2. S.L.Topalian, F.S.Hodi, J.R.Brahmer, S.N.Gettinger, D.C.Smith, D.F.McDermott, J.D.Powderly, R.D.Carvajal, J.A.Sosman, M.B.Atkins et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; 10.1056/NEJMoa1200690
3. J.Larkin, V.Chiarion-Sileni, R.Gonzalez, J.J.Grob, C.L.Cowey, C.D.Lao, D.Schadendorf, R.Dummer, M.Smylie, P.Rutkowski et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34; PMID:26027431; 10.1056/NEJMoa1504030
4. A.Snyder, V.Makarov, T.Merghoub, J.Yuan, J.M.Zaretsky, A.Desrichard, L.A.Walsh, M.A.Postow, P.Wong, T.S.Ho et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371:2189-99; PMID:25409260; 10.1056/NEJMoa1406498
5. M.M.Gubin, X.Zhang, H.Schuster, E.Caron, J.P.Ward, T.Noguchi, Y.Ivanova, J.Hundal, C.D.Arthur, W.J.Krebber et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515:577-81; PMID:25428507; 10.1038/nature13988
6. V.A.Brentville, R.L.Metheringham, B.Gunn, L.G.Durrant. High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment. PloS One 2012; 7:e41112; PMID:22829916; 10.1371/journal.pone.0041112
7. L.Lee, R.F.Wang, X.Wang, A.Mixon, B.E.Johnson, S.A.Rosenberg, D.S.Schrump. NY-ESO-1 may be a potential target for lung cancer immunotherapy. Cancer J Sci Am 1999; 5:20-5; PMID:10188057
8. A.Akcakanat, T.Kanda, T.Tanabe, S.Komukai, K.Yajima, S.Nakagawa, M.Ohashi, K.Hatakeyama. Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy. Int J Cancer 2006; 118:123-8; PMID:16003736; 10.1002/ijc.21219
9. T.Nicholaou, L.Ebert, I.D.Davis, N.Robson, O.Klein, E.Maraskovsky, W.Chen, J.Cebon. Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol 2006; 84:303-17; PMID:16681828; 10.1111/j.1440-1711.2006.01446.x
10. H.M.Zarour, B.Maillere, V.Brusic, K.Coval, E.Williams, S.Pouvelle-Moratille, F.Castelli, S.Land, J.Bennouna, T.Logan et al. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res 2002; 62:213-8; PMID:11782380
11. H.Yamaguchi, F.Tanaka, M.Ohta, H.Inoue, M.Mori. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response. Clin Cancer Res 2004; 10:890-6; PMID:14871964; 10.1158/1078-0432.CCR-1086-3
12. M.Mandic, F.Castelli, B.Janjic, C.Almunia, P.Andrade, D.Gillet, V.Brusic, J.M.Kirkwood, B.Maillere, H.M.Zarour. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol 2005; 174:1751-9; PMID:15661941; 10.4049/jimmunol.174.3.1751
13. E.Jager, S.Gnjatic, Y.Nagata, E.Stockert, D.Jager, J.Karbach, A.Neumann, J.Rieckenberg, Y.T.Chen, G.Ritter et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 2000; 97:12198-203; PMID:11027314; 10.1073/pnas.220413497
14. P.F.Robbins, R.A.Morgan, S.A.Feldman, J.C.Yang, R.M.Sherry, M.E.Dudley, J.R.Wunderlich, A.V.Nahvi, L.J.Helman, C.L.Mackall et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29:917-24; PMID:21282551; 10.1200/JCO.2010.32.2537
15. E.Jager, J.Karbach, S.Gnjatic, A.Neumann, A.Bender, D.Valmori, M.Ayyoub, E.Ritter, G.Ritter, D.Jager et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA 2006; 103:14453-8; PMID:16984998; 10.1073/pnas.0606512103
16. A.Bender, J.Karbach, A.Neumann, D.Jager, S.E.Al-Batran, A.Atmaca, E.Weidmann, M.Biskamp, S.Gnjatic, L.Pan et al. LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun 2007; 7:16; PMID:17944437
17. Q.Chen, H.Jackson, M.Shackleton, P.Parente, W.Hopkins, S.Sturrock, D.MacGregor, E.Maraskovsky, T.Y.Tai, N.Dimopoulos et al. Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination. Cancer Immun 2005; 5:5; PMID:15755075
18. R.L.Metheringham, V.A.Pudney, B.Gunn, M.Towey, I.Spendlove, L.G.Durrant. Antibodies designed as effective cancer vaccines. mAbs 2009; 1:71-85; PMID:20046577; 10.4161/mabs.1.1.7492
19. V.A.Pudney, R.L.Metheringham, B.Gunn, I.Spendlove, J.M.Ramage, L.G.Durrant. DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells. Eur J Immunol 2010; 40:899-910; PMID:20039301; 10.1002/eji.200939857
20. P.Chiarella, E.Massi, M.De Robertis, A.Sibilio, P.Parrella, V.M.Fazio, E.Signori. Electroporation of skeletal muscle induces danger signal release and antigen-presenting cell recruitment independently of DNA vaccine administration. Expert Opin Biol Ther 2008; 8:1645-57; PMID:18847301; 10.1517/14712598.8.11.1645
21. S.van Drunen Littel-van den Hurk, D.Hannaman. Electroporation for DNA immunization: clinical application. Expert Rev Vaccines 2010; 9:503-17; PMID:20450325; 10.1586/erv.10.42
22. M.Poulam, C.O.C.M.Patel, P.Lorigan, R.Plummer, D.Hannaman, M.Cunnell, R.Metheringham, V.Brentville, I.Daniel, L.Machado et al. An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells in vivo, in fully resected melanoma patients. ASCO Annual Meet 2015
23. E.Jager, Y.Nagata, S.Gnjatic, H.Wada, E.Stockert, J.Karbach, P.R.Dunbar, S.Y.Lee, A.Jungbluth, D.Jager et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 2000; 97:4760-5; PMID:10781081; 10.1073/pnas.97.9.4760
24. G.Bioley, C.Dousset, A.Yeh, B.Dupont, N.Bhardwaj, G.Mears, L.J.Old, M.Ayyoub, D.Valmori. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire. Clin Cancer Res 2009; 15:4467-74; PMID:19531622; 10.1158/1078-0432.CCR-09-0582
25. H.M.Zarour, W.J.Storkus, V.Brusic, E.Williams, J.M.Kirkwood. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res 2000; 60:4946-52; PMID:10987311
26. M.Ayyoub, P.Pignon, D.Dojcinovic, I.Raimbaud, L.J.Old, I.Luescher, D.Valmori. Assessment of vaccine-induced CD4 T cell responses to the 119-143 immunodominant region of the tumor-specific antigen NY-ESO-1 using DRB1*0101 tetramers. Clin Cancer Res 2010; 16:4607-15; PMID:20670945; 10.1158/1078-0432.CCR-10-1485
27. L.Lopes, M.Dewannieux, U.Gileadi, R.Bailey, Y.Ikeda, C.Whittaker, M.P.Collin, V.Cerundolo, M.Tomihari, K.Ariizumi et al. Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J Virol 2008; 82:86-95; PMID:17959670; 10.1128/JVI.01289-07
28. G.J.MacArthur, A.D.Wilson, M.A.Birchall, A.J.Morgan. Primary CD4+ T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cells. J Virol 2007; 81:4766-75; PMID:17314172; 10.1128/JVI.02608-06
29. A.Perez-Diez, N.T.Joncker, K.Choi, W.F.Chan, C.C.Anderson, O.Lantz, P.Matzinger. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109:5346-54; PMID:17327412; 10.1182/blood-2006-10-051318
30. V.Deffrennes, J.Vedrenne, M.C.Stolzenberg, J.Piskurich, G.Barbieri, J.P.Ting, D.Charron, C.Alcaide-Loridan. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter. J Immunol 2001; 167:98-106; PMID:11418637; 10.4049/jimmunol.167.1.98
31. B.Mach, V.Steimle, E.Martinez-Soria, W.Reith. Regulation of MHC class II genes: lessons from a disease. Ann Rev Immunol 1996; 14:301-31; PMID:8717517; 10.1146/annurev.immunol.14.1.301
32. V.Steimle, C.A.Siegrist, A.Mottet, B.Lisowska-Grospierre, B.Mach. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994; 265:106-9; PMID:8016643; 10.1126/science.8016643
33. Z.Zhu, V.Singh, S.K.Watkins, V.Bronte, J.L.Shoe, L.Feigenbaum, A.A.Hurwitz. High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res 2013; 73:595-604; PMID:23204239; 10.1158/0008-5472.CAN-12-1123
34. S.Onizuka, I.Tawara, J.Shimizu, S.Sakaguchi, T.Fujita, E.Nakayama. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59:3128-33; PMID:10397255
35. R.P.Sutmuller, L.M.van Duivenvoorde, A.van Elsas, T.N.Schumacher, M.E.Wildenberg, J.P.Allison, R.E.Toes, R.Offringa, C.J.Melief. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194:823-32; PMID:11560997; 10.1084/jem.194.6.823
36. A.J.Rech, R.H.Vonderheide. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009; 1174:99-106; PMID:19769742; 10.1111/j.1749-6632.2009.04939.x
37. S.Walter, T.Weinschenk, A.Stenzl, R.Zdrojowy, A.Pluzanska, C.Szczylik, M.Staehler, W.Brugger, P.Y.Dietrich, R.Mendrzyk et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18:1254-61; PMID:22842478; 10.1038/nm.2883
38. J.F.Grosso, M.N.Jure-Kunkel. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013; 13:5; PMID:23390376
39. P.Shrikant, A.Khoruts, M.F.Mescher. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 1999; 11:483-93; PMID:10549630; 10.1016/S1074-7613(00)80123-5
40. M.A.Curran, W.Montalvo, H.Yagita, J.P.Allison. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010; 107:4275-80; PMID:20160101; 10.1073/pnas.0915174107
41. S.Spranger, R.M.Spaapen, Y.Zha, J.Williams, Y.Meng, T.T.Ha, T.F.Gajewski. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5:200ra116; PMID:23986400; 10.1126/scitranslmed.3006504
42. K.Abiko, N.Matsumura, J.Hamanishi, N.Horikawa, R.Murakami, K.Yamaguchi, Y.Yoshioka, T.Baba, I.Konishi, M.Mandai. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer 2015; 112:1501-9; PMID:25867264; 10.1038/bjc.2015.101
43. R.H.Thompson, S.M.Kuntz, B.C.Leibovich, H.Dong, C.M.Lohse, W.S.Webster, S.Sengupta, I.Frank, A.S.Parker, H.Zincke et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006; 66:3381-5; PMID:16585157; 10.1158/0008-5472.CAN-05-4303
44. R.Hino, K.Kabashima, Y.Kato, H.Yagi, M.Nakamura, T.Honjo, T.Okazaki, Y.Tokura. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010; 116:1757-66; PMID:20143437; 10.1002/cncr.24899
45. D.E.Dolan, S.Gupta. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control 2014; 21:231-7; PMID:24955707
46. R.S.Herbst, J.C.Soria, M.Kowanetz, G.D.Fine, O.Hamid, M.S.Gordon, J.A.Sosman, D.F.McDermott, J.D.Powderly, S.N.Gettinger et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-7; PMID:25428504; 10.1038/nature14011
47. C.Robert, G.V.Long, B.Brady, C.Dutriaux, M.Maio, L.Mortier, J.C.Hassel, P.Rutkowski, C.McNeil, E.Kalinka-Warzocha et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-30; PMID:25399552; 10.1056/NEJMoa1412082
48. L.M.Francisco, V.H.Salinas, K.E.Brown, V.K.Vanguri, G.J.Freeman, V.K.Kuchroo, A.H.Sharpe. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206:3015-29; PMID:20008522; 10.1084/jem.20090847
49. W.Wang, R.Lau, D.Yu, W.Zhu, A.Korman, J.Weber. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol 2009; 21:1065-77; PMID:19651643; 10.1093/intimm/dxp072
50. T.R.Simpson, F.Li, W.Montalvo-Ortiz, M.A.Sepulveda, K.Bergerhoff, F.Arce, C.Roddie, J.Y.Henry, H.Yagita, J.D.Wolchok et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210:1695-710; PMID:23897981; 10.1084/jem.20130579
51. D.Rohlman, S.Punj, J.Pennington, S.Bradford, N.I.Kerkvliet. Suppression of acute graft-versus-host response by TCDD is independent of the CTLA-4-IFN-gamma-IDO pathway. Toxicol Sci 2013; 135:81-90; PMID:23798565; 10.1093/toxsci/kft140
52. E.Jager, Y.T.Chen, J.W.Drijfhout, J.Karbach, M.Ringhoffer, D.Jager, M.Arand, H.Wada, Y.Noguchi, E.Stockert et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187:265-70; PMID:9432985; 10.1084/jem.187.2.265
53. J.L.Chen, P.R.Dunbar, U.Gileadi, E.Jager, S.Gnjatic, Y.Nagata, E.Stockert, D.L.Panicali, Y.T.Chen, A.Knuth et al. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol 2000; 165:948-55; PMID:10878370; 10.4049/jimmunol.165.2.948
54. D.Valmori, V.Dutoit, D.Lienard, D.Rimoldi, M.J.Pittet, P.Champagne, K.Ellefsen, U.Sahin, D.Speiser, F.Lejeune et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer research 2000; 60:4499-506; PMID:10969798
55. Q.Chen, H.Jackson, P.Parente, T.Luke, M.Rizkalla, T.Y.Tai, H.C.Zhu, N.A.Mifsud, N.Dimopoulos, K.A.Masterman et al. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci USA 2004; 101:9363-8; PMID:15197261; 10.1073/pnas.0403271101
56. R.Y.Zhao, N.A.Mifsud, K.Xiao, K.F.Chan, S.Oveissi, H.M.Jackson, N.Dimopoulos, P.Guillaume, A.J.Knights, T.Lowen et al. A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen. PloS One 2012; 7:e44707; PMID:22970293; 10.1371/journal.pone.0044707
57. H.Benlalam, B.Linard, Y.Guilloux, A.Moreau-Aubry, L.Derre, E.Diez, B.Dreno, F.Jotereau, N.Labarriere. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J Immunol 2003; 171:6283-9; PMID:14634146; 10.4049/jimmunol.171.11.6283
58. E.Jager, J.Karbach, S.Gnjatic, D.Jager, M.Maeurer, A.Atmaca, M.Arand, J.Skipper, E.Stockert, Y.T.Chen et al. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. Cancer Immun 2002; 2:12; PMID:12747757
59. S.Gnjatic, Y.Nagata, E.Jager, E.Stockert, S.Shankara, B.L.Roberts, G.P.Mazzara, S.Y.Lee, P.R.Dunbar, B.Dupont et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci USA 2000; 97:10917-22; PMID:11005863; 10.1073/pnas.97.20.10917
60. Y.Mizote, T.Taniguchi, K.Tanaka, M.Isobe, H.Wada, T.Saika, S.Kita, Y.Koide, A.Uenaka, E.Nakayama. Three novel NY-ESO-1 epitopes bound to DRB1*0803, DQB1*0401 and DRB1*0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients. Vaccine 2010; 28(32):5338-5346; PMID:20665979; 10.1016/j.vaccine.2010.05.044
61. E.Jager, D.Jager, J.Karbach, Y.T.Chen, G.Ritter, Y.Nagata, S.Gnjatic, E.Stockert, M.Arand, L.J.Old et al. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 2000; 191:625-30; PMID:10684854; 10.1084/jem.191.4.625
62. A.J.Knights, N.Nuber, C.W.Thomson, O.de la Rosa, E.Jager, J.M.Tiercy, M.van den Broek, S.Pascolo, A.Knuth, A.Zippelius. Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunol Immunother 2009; 58:325-38; PMID:18663444; 10.1007/s00262-008-0556-8
63. J.Matsuzaki, F.Qian, I.Luescher, S.Lele, G.Ritter, P.A.Shrikant, S.Gnjatic, L.J.Old, K.Odunsi. Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. Cancer Immunol Immunother 2008; 57:1185-95; PMID:18253733; 10.1007/s00262-008-0450-4
64. H.Nagai, T.Horikawa, I.Hara, A.Fukunaga, S.Oniki, M.Oka, C.Nishigori and M.Ichihashi. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Experimental dermatology. 2004; 13(10):613-620; PMID:15447721